DORIBAX
LOE ApproachingNDAINTRAVENOUSINJECTABLE
Approved
Oct 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORIBAX (ertapenem) is an intravenous carbapenem antibiotic approved in 2007 for treating serious bacterial infections. The drug works by inhibiting bacterial cell wall synthesis, making it effective against gram-positive and gram-negative pathogens. It is used primarily in hospital settings for complicated intra-abdominal infections, urinary tract infections, and other serious infections.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting team and shift toward cost management and retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DORIBAX offers limited career growth opportunities due to its LOE approaching status and zero linked job postings. Professionals joining this product should expect focus on defensive commercial strategies, cost optimization, and transition planning rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on DORIBAX at Shionogi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.